FGEN (Common Stock)
ExchangeNASDAQ (US Dollar)
Change (%) Stock is Down 0.3 (1.24%)
Data as of 01/24/17 1:52 p.m. ET
Refresh quote
FibroGen is a research-based biotechnology company using its expertise in connective tissue growth factor (CTGF) and hypoxia-inducible factor (HIF) biology to discover, develop, and commercialize novel therapeutics for serious unmet medical needs.
Recent Press ReleasesMore »
01/20/17Pamrevlumab Pancreatic Cancer Clinical Data Presented at ASCO 2017 Gastrointestinal Cancers SymposiumPrinter Friendly Version
11/08/16FibroGen Reports Financial Results for the Third Quarter of 2016 and Provides Corporate UpdatePrinter Friendly Version
11/01/16FibroGen to Report Third Quarter 2016 Financial Results on November 8, 2016Printer Friendly Version
10/31/16FibroGen Completes Enrollment in Roxadustat Phase 3 Studies in ChinaPrinter Friendly Version
Upcoming EventsMore »
There are currently no events scheduled.
Data provided by Nasdaq. Minimum 15 minutes delayed. View Attributions and Sources